Provided by Tiger Fintech (Singapore) Pte. Ltd.

Larimar Therapeutics, Inc.

2.01
+0.10005.24%
Post-market: 2.050.0400+1.99%18:26 EDT
Volume:1.16M
Turnover:2.32M
Market Cap:128.70M
PE:-1.53
High:2.06
Open:1.88
Low:1.87
Close:1.91
Loading ...

Company Profile

Company Name:
Larimar Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
65
Office Location:
Three Bala Plaza East,Suite 506,Bala Cynwyd,Pennsylvania,United States
Zip Code:
19004
Fax:
- -
Introduction:
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Directors

Name
Position
Peter Barrett
Chairman of the Board
Thomas E. Hughes
President, Chief Executive Officer and Director
Bruce Booth
Director
Cameron Geoffrey McDonough
Director
Frances K. Heller
Director
Frank E. Thomas
Director
John L. LaMattina
Director
Robert J. Perez
Director
Thomas O. Daniel
Director

Shareholders

Name
Position
Thomas E. Hughes
President, Chief Executive Officer and Director
Patricia L. Allen
Chief Financial Officer
Dennis D. Kim
Chief Medical Officer